Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Mesoblast Limited — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.49, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| BOTZ | MESO | |
|---|---|---|
52-Week High | $41.63 | $20.96 |
52-Week Low | $31.99 | $12.88 |
Market Cap | — | $2.16B |
Sector | — | Technology |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.61, up 1.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, offering exposure to global leaders in automation. Recent news highlights its role in the expanding AI and robotics theme, with comparisons to peers like ARKQ and ROBO. A small dividend is scheduled for 2026.
Outlook is positive due to growth in AI and robotics adoption, but risks include high valuation sensitivity and sector competition. Investors should weigh the thematic growth potential against market volatility and the ETF's expense structure.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
